Immunotherapy: When to initiate treatment in children

Allergy and Asthma Proceedings

Volumn 28, Issue 6, 2007, Pages 698-705

  Finegold, Ira ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Age to begin immunotherapy; Allergic reactions; Allergy in children; Asthma; Guidelines; Immunotherapy; Mechanisms; Prevention; SCIT; SLIT

Indexed keywords

ALLERGEN;

ARTICLE; ASTHMA; CHILD; DESENSITIZATION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; PRESCHOOL CHILD; RISK ASSESSMENT;

ALLERGENS; ASTHMA; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; RISK ASSESSMENT;

EID: 38349171728     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.3053     Document Type: Article

References (41)

1. Li JT, Lockey RF, Portnoy JM, et al. (Eds). Immunotherapy: A practice parameter. Ann Allergy Asthma Immunol 90:S1-S40, 2003.
2. Finegold I. Is immunotherapy effective in allergic disease? Curr Opin Allergy Clin Immunol 2:537-540, 2002.
3. Grady D. An epidemic no one understands. NY Times November 28, 2006.
4. Eder W, Ege MJ, and von Mutius E. The asthma epidemic. N Engl J Med 355:2226-2235, 2006.
5. Nelson HS. Immunotherapy for inhalant allergens. In Middleton's Allergy Principles and Practice. Adkinson NF, Yunginger JW, Busse WW, et al. (Eds). St. Louis, MO: Mosby, 1455-1473, 2003.
6. Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 113:1013-1023, 2004.
7. Till SJ, Francis JN, Nouri-Aria K, and Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 113:1025-1034, 2004.
8. Nelson H. Allergen immunotherapy: Where is it now? J Allergy Clin Immunol 119:769-777, 2007.
9. Ebner C, Sieman U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1 p1, a major grass pollen allergen. Clin Exp Allergy 27:1007-1015, 1997.
10. Robinson DS, Larche M, and Durham SR. T regs and allergic disease. J Clin Invest 114:1389-1397, 2004.
11. Adkis M, and Adkis C. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119:780-789, 2007.
12. Peat JK, Tovey E, Gray EJ, et al. Asthma severity and morbidity in a population sample of Sydney schoolchildren: Part II - Importance of house dust mite allergens. Aust N Z J Med 24:270-276, 1994.
13. Fichier CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52:274-283, 1997.
14. Abramson MJ, Puy RM, and Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 4:CD001186, 2003.
15. Ross RN, Nelson HS, and Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: A meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 22:329-341, 2000.
16. Johnstone DE, and Dutton A. The value of hyposensitization therapy for bronchial asthma in children. Pediatrics 42:793-802, 1968.
17. Cools M, Van Bever HP, and Weyler JJ. Long-term effects of specific immunotherapy administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 55:69-73, 2000.
18. Eng PA, Borer-Reinhold M, Heijnen IAFM, and Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61:198-201, 2006.
19. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study) J Allergy Clin Immunol 109251-256, 2002.
20. Niggemann B, Jacobsen L, Dreborg S, et al. and PAT Investigator Group. Five-year follow-up on the PAT study: Specific immunotherapy and long-term prevention of asthma in children. Allergy 61:855-859, 2006.
21. Johnstone DE, and Crump L. Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 27: 39-44, 1961.
22. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitization in children. J Allergy Clin Immunol 99:450-453, 1997.
23. Pajno GB, Barberio G, De Luca F, et. al. Prevention of new sensitization in asthmatic children monosensitized to house dust mite by specific immunotherapy: A six-year, follow-up study. Clin Exp Allergy 31:1392-1397, 2001.
24. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitization in monosensitized subjects submitted to specific immunotherapy or not: A retrospective study. Clin Exp Allergy 31:1295-1302, 2001.
25. Fireman P. Chapter 20: Primary immunodeficiency disease. In Atlas of Allergies and Clinical Immunology. Fireman P (Ed). Philadelphia, PA: Mosby, Inc., 332, 2006.
26. LeMasters GK, Wilson K, Levin L, et al. High Prevalence of aeroallergen sensitization among infants of atopic parents. J Pediatr 149:505-511, 2006.
27. Cox L, Li J, Nelson H, et al. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol 120:S25-S85, 2007.
28. Bragagnza SC, Braganza JP, Acworth DRL, et al. Paediatric emergency department anaphylaxis: Different patterns from adults. Arch Dis Child 91:159-163, 2006.
29. Brown AF, McKinnon D, and Chu K. Emergency department anaphylaxis: A review of 142 patients in a single year. J Allergy Clin Immunol 108:861-866, 2001.
30. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 30:1144-1150, 2000.
31. Mailing H, and Weeke B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy 48(suppl 14):9-35, 1993.
32. Ownby DR, and Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol 94:662-665, 1994.
33. Canadian parameters immunotherapy. CMAJ Can Med Assoc J 173(suppl 6):S46-S50, 2005.
34. Hejjaoui A, Dhivert H, Michel F, and Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 85:473-479, 1990.
35. Roberts G, Hurley C, Turcanu V, and Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 117:263-268, 2006.
36. Rodriguez Perez N, and de Jesus Ambriz Moreno M. Safety of immunotherapy and cutaneous tests with allergens in children under 5 years of age. Rev Alerg Mex 53:47-51, 2006.
37. Cantani A, and Micera M. A prospective study of asthma desensitization in 1,182 children, 592 asthmatic children, and 590 nonatopic controls. Eur Rev Med Pharmacol 9:325-329, 2005.
38. Agostinis F, Tellarini L, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 60:133, 2005.
39. Fiocchi A, Pajno G, La Grutta S, et. Al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma, Immunol 95:254-258, 2005.
40. DiRienzo V, Minelli M, Musarra A, et al. Post marketing survey on the safety of sub lingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 35:560-564, 2005.
41. Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 117:1021-1035, 2006.